The combination of PC and topotecan to human prostate adenocarcinoma cells (LNCaP) increased the activity of caspase-9 and caspase-3, increased free radical oxygen (ROS) levels, induced apoptosis of tumor cells, and reduced side effects of topotecan in a rat tumor model [104]. This evidence concerns the gene CASP9 and neoplasm.